NCT03581487 2025-11-05Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung CancerM.D. Anderson Cancer CenterPhase 1/2 Completed40 enrolled
NCT03212469 2025-05-08ABIMMUNEGustave Roussy, Cancer Campus, Grand ParisPhase 1/2 Completed54 enrolled